Skip to main content

Table 3 Cost-effectiveness, Sensitivity Analysis

From: Cost-effectiveness and budget impact of the management of uncomplicated urinary tract infection by community pharmacists

Strategy

Mean Costs, $

Mean Effects, QALMs

Incremental Costs, $

Incremental Effects, QALMs

ICER†, $/QALM gained

Cure rate of community pharmacist-initiated antibiotic-treatment (86%)

Community pharmacist-initiated

72.81 (49.77; 99.77)

0.75229 (0.51536; 0.92437)

–

–

–

Family physician-initiated

142.01 (95.73; 197.40)

0.75233 (0.51488; 0.92407)

69.20 (15.50; 129.40)

0.00004 (−0.00726; 0.00698)

1,730,000

Emergency physician-initiated

371.09 (232.14; 546.54)

0.75237 (0.51973; 0.92503)

–

–

Extended dominance

Cure rate of community pharmacist-initiated antibiotic-treatment (83%)

Community pharmacist-initiated

72.90 (50.07; 100.88)

0.75326 (0.52212; 0.92515)

–

–

–

Family physician-initiated

141.74 (94.71; 197.46)

0.75328 (0.52284; 0.92450)

68.85 (14.61; 129.57)

0.00002 (−0.00714; 0.00701)

3,442,500

Emergency physician-initiated

370.36 (229.47; 546.86)

0.75333 (0.52349; 0.92436)

–

–

Extended dominance

  1. †Sequential analysis